Associations - HER-2 L755S

HER-2 L755S	HER2 Negative Breast Cancer	HER-2 L755S	HER2 Negative Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
HER-2 L755S	HER2 Negative Breast Cancer	HER-2 L755S	HER2 Negative Breast Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 L755S	Salivary Gland Cancer	HER-2 L755S	Salivary Gland Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 L755S	Triple Negative Breast Cancer	HER-2 L755S	Triple Negative Breast Cancer	neratinib Sensitive: C4 – Case Studies neratinib Sensitive : C4	neratinib Sensitive: C4 – Case Studies neratinib Sensitive : C4
HER-2 L755S	HER2 Positive Breast Cancer	HER-2 L755S	HER2 Positive Breast Cancer	tucatinib Resistant: D – Preclinical tucatinib Resistant : D	tucatinib Resistant: D – Preclinical tucatinib Resistant : D
HER-2 L755S	Colorectal Cancer	HER-2 L755S	Colorectal Cancer	panitumumab Resistant: D – Preclinical panitumumab Resistant : D	panitumumab Resistant: D – Preclinical panitumumab Resistant : D
HER-2 L755S	HER2 Positive Breast Cancer	HER-2 L755S	HER2 Positive Breast Cancer	trastuzumab + tucatinib Resistant: D – Preclinical trastuzumab + tucatinib Resistant : D	trastuzumab + tucatinib Resistant: D – Preclinical trastuzumab + tucatinib Resistant : D
HER-2 L755S	HER2 Positive Breast Cancer	HER-2 L755S	HER2 Positive Breast Cancer	neratinib Resistant: D – Preclinical neratinib Resistant : D	neratinib Resistant: D – Preclinical neratinib Resistant : D
HER-2 L755S	HER2 Positive Breast Cancer	HER-2 L755S	HER2 Positive Breast Cancer	lapatinib Resistant: D – Preclinical lapatinib Resistant : D	lapatinib Resistant: D – Preclinical lapatinib Resistant : D
HER-2 L755S	Gastric Cancer	HER-2 L755S	Gastric Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 L755S	Colorectal Cancer	HER-2 L755S	Colorectal Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	ado-trastuzumab emtansine Resistant: D – Preclinical ado-trastuzumab emtansine Resistant : D	ado-trastuzumab emtansine Resistant: D – Preclinical ado-trastuzumab emtansine Resistant : D
HER-2 L755S	Non Small Cell Lung Cancer	HER-2 L755S	Non Small Cell Lung Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 L755S	Gastric Cancer	HER-2 L755S	Gastric Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 L755S	Gastric Cancer	HER-2 L755S	Gastric Cancer	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D
HER-2 L755S	Colorectal Cancer	HER-2 L755S	Colorectal Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	lapatinib Resistant: D – Preclinical lapatinib Resistant : D	lapatinib Resistant: D – Preclinical lapatinib Resistant : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	AEE788 Sensitive: D – Preclinical AEE788 Sensitive : D	AEE788 Sensitive: D – Preclinical AEE788 Sensitive : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 L755S	HER2 Negative Breast Cancer	HER-2 L755S	HER2 Negative Breast Cancer	lapatinib Resistant: D – Preclinical lapatinib Resistant : D	lapatinib Resistant: D – Preclinical lapatinib Resistant : D
HER-2 L755S	Gastric Cancer	HER-2 L755S	Gastric Cancer	lapatinib Resistant: D – Preclinical lapatinib Resistant : D	lapatinib Resistant: D – Preclinical lapatinib Resistant : D
HER-2 L755S	Gastric Cancer	HER-2 L755S	Gastric Cancer	AEE788 Sensitive: D – Preclinical AEE788 Sensitive : D	AEE788 Sensitive: D – Preclinical AEE788 Sensitive : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	neratinib Resistant: D – Preclinical neratinib Resistant : D	neratinib Resistant: D – Preclinical neratinib Resistant : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D